Fig. 1: Schematic illustration of engineering of a multifunctional anti-thrombotic nanotherapy for targeted treatment of deep vein thrombosis (DVT) during pregnancy. | Nature Communications

Fig. 1: Schematic illustration of engineering of a multifunctional anti-thrombotic nanotherapy for targeted treatment of deep vein thrombosis (DVT) during pregnancy.

From: Functionally integrating nanoparticles alleviate deep vein thrombosis in pregnancy and rescue intrauterine growth restriction

Fig. 1

a Development of a nanotherapy with multiple bioactivities by self-assembly of a multifunctional low molecular weight heparin (LMWH) derivative (i.e., CTLH). Covalent conjugation of LMWH with bioactive moieties of linoleic acid (LA) and Tempol affords an amphiphile with multiple pharmacological activities, which is further functionalized with a thrombus-targeting peptide CREKA to obtain CTLH that can assemble into a multifunctional nanotherapy CTLH NP. b A sketch showing targeted treatment of DVT in pregnant rats by CTLH NP.

Back to article page